The Mouse Phenome Database (MPD) provides access to primary experimental trait data, genotypic variation, protocols and analysis tools for mouse genetic studies. Data are contributed by investigators worldwide and represent a broad scope of phenotyping endpoints and disease-related traits in naïve mice and those exposed to drugs, environmental agents or other treatments. MPD ensures rigorous curation of phenotype data and supporting documentation using relevant ontologies and controlled vocabularies. As a repository of curated and integrated data, MPD provides a means to access/re-use baseline data, as well as allows users to identify sensitized backgrounds for making new mouse models with genome editing technologies, analyze trait co-inheritance, benchmark assays in their own laboratories, and many other research applications. MPD’s primary source of funding is NIDA. For this reason, a majority of MPD data is neuro- and behavior-related.

This talks discusses data sharing in the context of dementia. It explains why data sharing in dementia is important, how data is usually shared in the field and illustrates two examples: the Netherlands Consortium Dementia cohorts and the European Platform for Neurodegenerative Diseases.

The Medical Informatics Platform (MIP) Dementia had been installed in several memory clinics across Europe allowing them to federate their real-world databases. Research open access databases had also been integrated such as ADNI (Alzheimer’s Dementia Neuroimaging Initiative), reaching a cumulative case load of more than 5,000 patients (major cognitive disorder due to Alzheimer’s disease, other major cognitive disorder, minor cognitive disorder, controls). The statistic and machine learning tools implemented in the MIP allowed researchers to conduct easily federated analyses among Italian memory clinics (Redolfi et al. 2020) and also across borders between the French (Lille), the Swiss (Lausanne) and the Italian (Brescia) datasets.

The number of patients with dementia is estimated to increase given the aging population. This will lead to a number of challenges in the future in terms of diagnosis and care for patients with dementia. To meet these needs such as early diagnsosis and development of prognostic biomarkers, large datasets, such as the federated datasets on dementia. The EAN Dementia and cognitive disorders scientific panel can play an important role as coordinator and connecting panel members who wish to participate in e.g. consortia.